{"filing":{"accession_number":"0001193125-26-272814","cik":"0001479615","ticker":"SLNCF","company_name":"Silence Therapeutics plc","form":"8-K","filing_date":"2026-06-16","report_date":null,"primary_document":"sln-20260616.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1479615/000119312526272814/sln-20260616.htm"},"events":[{"id":11382,"run_id":9991,"accession_number":"0001193125-26-272814","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This 8-K Item 5.07 discloses the results of Silence Therapeutics plc's 2026 Annual General Meeting held on June 16, 2026, with detailed voting tallies for nine resolutions including director re-appointments (Rhonda Hellums, James Ede-Golightly), advisory compensation vote, auditor ratification and re-appointment, and approval of annual accounts and remuneration reports. All resolutions passed. This is a standard shareholder vote results disclosure that would be material to investors assessing governance and board composition.","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-06-16","form":"8-K","submitted_at":null,"items":[{"id":7960,"accession_number":"0001193125-26-272814","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Silence Therapeutics plc's 2026 Annual General Meeting held on June 16, 2026, with detailed voting tallies for nine resolutions including director re-appointments (Rhonda Hellums, James Ede-Golightly), advisory compensation vote, auditor ratification and re-appointment, and approval of annual accounts and remuneration reports. All resolutions passed. This is a standard shareholder vote results disclosure that would be material to investors assessing governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T21:01:12.793343+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7960,"accession_number":"0001193125-26-272814","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This 8-K Item 5.07 discloses the results of Silence Therapeutics plc's 2026 Annual General Meeting held on June 16, 2026, with detailed voting tallies for nine resolutions including director re-appointments (Rhonda Hellums, James Ede-Golightly), advisory compensation vote, auditor ratification and re-appointment, and approval of annual accounts and remuneration reports. All resolutions passed. This is a standard shareholder vote results disclosure that would be material to investors assessing governance and board composition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T21:01:12.793343+00:00","company_name":"Silence Therapeutics plc","ticker":"SLNCF","filing_date":"2026-06-16"}]}